الفهرس 
Aim of the workOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified a mid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. It was initially reported to the WHO on December 2019. On March 2020, the WHO declared COVID-19 as a global pandemic. Respiratory system is the most impacted by the disease.
This pandemic has created a significant burden in all areas of life, especially economy and health. Different clinical features and risk factors related to hospitalization and mortality such as advanced age, male sex, and obesity, have been defined. PCR is the gold standard for diagnosis of covid 19. Radiological imaging has a fundamental role in the diagnostic process, management, and follow-up of Covid 19. Given its high sensitivity, chest computed tomography (CT), particularly high-resolution CT (HRCT), is the diagnostic method of choice in evaluating COVID-19 pneumonia, particularly when associated with disease progression. Currently, a variety of therapeutic options are available that include antiviral drugs, anti-SARS-CoV-2 monoclonal antibodies anti-inflammatory drugs, immunomodulators agents are available under FDA issued Emergency Use Authorization (EUA) or being evaluated in the management of COVID-19. The clinical utility of these treatments is specific and is based on the severity of illness or certain risk factors. This study is a retrospective / prospective cross sectional study which has been done on 299 patients attended to shebin el kom chest hospital confirmed by PCR.
We aimed to study Predictors of mortality among COVID 19 patints in Shebin El Kom Chest Hospital.